Visualizing the Evolution of Evidence: Cumulative Network Meta-Analyses of New Generation Antidepressants in the Last 40 Years. by Luo, Yan et al.
This article has been accepted for publication and undergone full peer review but has not been through 
the copyediting, typesetting, pagination and proofreading process which may lead to differences 
between this version and the Version of Record. Please cite this article as doi: 10.1002/jrsm.1413 
 
Title page  
Title 
Visualizing the Evolution of Evidence: Cumulative Network Meta-Analyses of New Generation 
Antidepressants in the Last 40 Years 
 
Authors 
Yan Luo1, lilacluo@gmail.com 
Anna Chaimani2, anna.chaimani@parisdescartes.fr 
Toshi A Furukawa1, furukawa@kuhp.kyoto-u.ac.jp 
Yuki Kataoka3, youkiti@gmail.com 
Yusuke Ogawa4, ogawa.yusuke.2u@kyoto-u.ac.jp 
Andrea Cipriani5, andrea.cipriani@psych.ox.ac.uk 
Georgia Salanti6, georgia.salanti@ispm.unibe.ch 
 
Affiliations 
1. Department of Health Promotion and Human Behavior, School of Public Health in the Graduate 
School of Medicine, Kyoto University, Kyoto, Japan 
2. Université de Paris, Research Center of Epidemiology and Statistics Sorbonne Paris Cité (CRESS-
UMR1153), INSERM, INRA, F-75004 Paris, France 
3. Hospital Care Research Unit, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, 
Japan 
4. Department of Healthcare Epidemiology, School of Public Health in the Graduate School of 
Medicine, Kyoto University, Kyoto, Japan 
5. Department of Psychiatry, University of Oxford, Oxford Health NHS Foundation Trust, 
Warneford Hospital, Oxford, UK 
6. Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland 
 
Corresponding author 
Toshi A Furukawa, MD, PhD 
Department of Health Promotion and Human Behavior, School of Public Health in the 
Graduate School of Medicine, Kyoto University, Yoshida Konoe-cho, Sakyo-ku, Kyoto 
606-8501, Japan 
Phone: +81-75-753-9491 
Fax: +81-75-753-4641 
This article is protected by copyright. All rights reserved.
s
o
u
r
c
e
:
 
h
t
t
p
s
:
/
/
d
o
i
.
o
r
g
/
1
0
.
7
8
9
2
/
b
o
r
i
s
.
1
4
3
9
2
6
 
|
 
d
o
w
n
l
o
a
d
e
d
:
 
2
7
.
1
2
.
2
0
2
0
  / 16 
 
Email: furukawa@kuhp.kyoto-u.ac.jp 
 
Word count 
3820 words 
Abstract 
It is often challenging to present the available evidence in a timely and comprehensible manner. We 
aimed to visualize the evolution of evidence about antidepressants for depression by conducting 
cumulative network meta-analyses (NMAs) and to examine whether it could have helped the selection 
of optimal drugs. We built a Shiny web application that performs and presents cumulative NMAs 
based on R netmeta. We used a comprehensive dataset of double-blind randomized controlled trials 
of 21 antidepressants in the acute treatment of major depression. The primary outcomes were efficacy 
(treatment response) and acceptability (all-cause discontinuation), and treatment effects were 
summarized via odds ratios. We evaluated the confidence in evidence using the CINeMA (Confidence 
in Network Meta-Analysis) framework for a series of consecutive NMAs. Users can change several 
conditions for the analysis, such as the period of synthesis, among the others. We present the league 
tables and two-dimensional plots that combine efficacy, acceptability and level of confidence in the 
evidence together, for NMAs conducted in 1990, 1995, 2000, 2005, 2010 and 2016. They reveal that 
through the past four decades, newly approved drugs often showed initially exaggerated results, which 
tended to diminish and stabilize after approximately a decade. Over the years, the drugs with relative 
superiority changed dramatically; but as the evidence network grew larger and better connected, the 
overall confidence improved. The Shiny app visualizes how evidence evolved over years, emphasizing 
the need for a careful interpretation of relative effects between drugs, especially for the potentially 
amplified performance of newly approved drugs.  
 
Keywords 
Visualization, network meta-analysis, confidence in the evidence, evidence evolution, shiny 
 
Ethics and dissemination 
This study is based on published and unpublished group-level data and do not require approval by an 
institutional review board. 
 
Trial registration number 
UMIN000031898. 
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INTRODUCTION 
Modern medicine has reached a consensus that clinical practice should be guided by up-to-date 
evidence. However, the evidence changes rapidly, as many new agents and interventions are developed 
at a high speed and an exploding amount of clinical studies are published every day. It remains a 
challenge for investigators and practicing clinicians to appreciate the existing evidence appropriately 
in a timely manner. A tool that synthesizes and presents the often fragmented and ever-growing body 
of evidence would be of great value.   
 
Evidence synthesis methods are developing fast. Pairwise meta-analyses can combine randomized 
controlled trials (RCTs) comparing two interventions. Network meta-analysis (NMA) enables the 
comprehensive and simultaneous comparison of multiple treatments. An empirical research has 
demonstrated that NMA, in comparison with pairwise meta-analysis, can increase statistical power 
and allow earlier detection of differences between treatment alternatives1. It is essential that the output 
from such an influential evidence resource like NMA is demonstrated in a succinct and understandable 
manner. 
 
The evidence for treating patients with depression offers a typical example. Although antidepressants 
have been recommended as the first-line treatment, it has not been easy for physicians to choose drugs 
with better efficacy and safety among the many available. Early evidence, mostly based on RCTs and 
pairwise meta-analyses, implied that antidepressants had comparable efficacy. However, in the past 
10 years, NMAs suggested that different antidepressants might have clinically important differences 
in efficacy and acceptability2,3. It is however unclear whether this evidence base, if available earlier, 
would have been able to indicate differences between the drugs and how evidence has evolved with 
additional trials.  
 
Although NMA can help answer questions like this, it is challenging to present its output, since it 
usually produces a multitude of information and findings, from network diagrams to pairwise treatment 
comparisons and tests for the underlying assumptions. Additionally, statements about the credibility 
of the main results from NMA are of great interest as they can limit or enhance the practical 
implications of the NMA findings. Previous studies have proposed several ways to visualize the results 
of NMAs4, yet no attempt has been made towards integrating the level of confidence in the evidence.  
 
Relevant statistical software is being developed in the last years. The open-source project R is 
increasingly used in evidence synthesis, with packages such as meta, rmeta and netmeta gaining 
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in importance5-9. The powerful graphing package ggplot2 greatly facilitates data visualization10. 
The CINeMA software, using the netmeta package and other self-programmed routines facilitates 
and simplifies the evaluation of the credibility in NMA results11. Finally, the shiny package in R makes 
it possible to build web applications that can take advantage of all R packages and display results 
interactively12. Making good use of these techniques can enhance visualization of the NMA output.  
 
In this article, we present a case where visualization of the NMA results via a Shiny application can 
provide insight to the evolution of evidence in terms of structure, results and credibility. We conducted 
a series of cumulative NMAs at several consecutive time points over the past 40 years. More 
specifically, we aim to: (1) visualize the evolution of evidence and the level of the confidence regarding 
the effects of antidepressants using plots which integrate efficacy, acceptability and confidence in the 
evidence; (2) examine whether visualization could have facilitated the selection of optimal drugs in 
earlier years. 
 
 
METHODS 
The protocol for this study has been published13. This study used group-level data and did not require 
approval by an institutional review board. It was registered at UMIN Clinical Trials Registry 
(identifier: UMIN000031898). 
 
Study selection 
We used aggregated study-level data identified and collected by GRISELDA (Group of Researchers 
Investigating Specific Efficacy of individual Drugs for Acute depression)3. A detailed description of 
the methods can be found in the protocol3,14. Briefly, published and unpublished double-blind RCTs 
of the acute phase treatment of adult patients (≥18 years old) with a primary diagnosis of major 
depression were included. The eligible drugs were: agomelatine, amitriptyline, bupropion, citalopram, 
clomipramine, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levomilnacipran, 
milnacipran, mirtazapine, nefazodone, paroxetine, reboxetine, sertraline, trazodone, venlafaxine, 
vilazodone and vortioxetine. Only study arms with drugs administered at doses within approved ranges 
by drug regulatory agencies were included in the analysis3.  
 
Data extraction 
In this study we used two primary outcomes, efficacy (measured as the response rate, i.e. the proportion 
of patients who showed a reduction of at least 50% on validated depression severity scales compared 
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to baseline at a time point as close to 8 weeks as possible between 4 to 12 weeks) and acceptability 
(measured as the proportion of patients who withdrew early due to any reasons).  
 
Since we aimed to show the evidence evolution, we conducted NMAs at different time periods. 
Different NMAs included RCTs conducted during different periods, thus we extracted the completion 
year of each trial. Publication date was used if the trial’s completion year could not be identified; and 
if both were unavailable, the date of approval by drug agencies was used.  
 
The dataset also comprises risk of bias assessments for each included RCT, based on the Cochrane 
Collaboration risk of bias tool15. The risk of bias (low, high or unclear) was evaluated for 7 domains 
(sequence generation, allocation concealment, blinding of participants, blinding of therapist, blinding 
of assessor, selective reporting bias and attrition bias) for each RCT. The domain-specific judgements 
were then summarized to obtain a total overall risk of bias for each study. A study was considered at 
low risk if none of the domains were assessed as high risk and three or less were rated as unclear risk; 
at moderate risk if one domain was of high risk, or none was high but four or more were assessed as 
unclear risk; in all the other situations studies were classified as having high risk of bias3,14.  
 
Data analysis 
We programmed a Shiny application that performs NMAs and presents the results interactively. The 
web app is accessible at https://cinema.ispm.unibe.ch/shinies/GRISELDA/, and several exemplar 
screen shots from the app are provided in the Appendix. We used the netmeta 1.1-0 package in R 
(version 3.6.0) to conduct NMA, and to produce the network diagrams, league tables and forest plots. 
We used ggplot2 package to draw two-dimensional plots combining both efficacy and acceptability.  
 
In the web app, NMAs can be performed under different conditions. Users can decide whether they 
want to see the results of an analysis from: (1) both placebo-controlled trials and head-to-head trials, 
or head-to-head trials only; (2) RCTs completed at any particular time period; and (3) both published 
and unpublished studies, or published studies only. For each NMA, a random-effects model was used 
to synthesize odds ratios (ORs) for both efficacy and acceptability. The transitivity assumption of the 
entire dataset was previously deemed plausible in the most recent analysis3. We examined the 
comparison-adjusted funnel plot to see if there were significant differences between precise and 
imprecise trials.  
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In the Results section of this article, we show a series of consecutively conducted NMAs (at 1990, 
1995, 2000, 2005, 2010 and 2016, respectively) in order to demonstrate the evolution of evidence, and 
each analysis includes RCTs completed up to 1 year before that date. These NMAs pertain to the 
dataset that includes unpublished studies but excludes placebo-controlled trials, as it was also the case 
in the original publication by Cipriani et al3. When interest lies in differences between drugs, placebo-
controlled trials can introduce heterogeneity and may compromise the transitivity assumption in the 
network16-21. We also assessed the confidence in the evidence for these NMAs, using the CINeMA 
(Confidence in Network Meta-Analysis) framework22-25 through the dedicated software11. The 
confidence in each NMA ORAB between two given drugs A and B was evaluated for six domains: 
within-trial bias, reporting bias, indirectness, imprecision, heterogeneity and incoherence. The 
software required some input in each domain in order to recommend whether there were ‘major 
concerns’, ‘some concerns’ or ‘no concerns’ for that particular domain. After judgements for all six 
domains, we summarized the overall confidence in evidence for each NMA ORAB into high, moderate, 
low and very low. For each drug, we calculated the percentage of the four levels based on all 
comparisons including that drug, combining both efficacy and acceptability. We therefore produced a 
level of confidence for the evidence provided for every single drug. More details on CINeMA can be 
found in23-25, and we also provide details of our considerations for assessment in the Appendix. 
Additionally, as CINeMA assessment requires some threshold values and evaluation rules to be 
decided, we finalized them through discussions. After determining these rules, the remaining synthesis 
of confidence in the evidence can be automatically calculated via CINeMA web app, hence one author 
finally input all the data and got the results. 
 
We provided the datasets, R script for the main analyses, and R script for the Shiny in 
https://github.com/y-luo06/cNMA_of_antidepressant. 
 
Results presentation and visualization 
The Shiny displays the following graphical and numerical information:  
1. Network plots and basic information for both efficacy and acceptability network. The 
basic information includes the number of studies, the list of treatments, and some statistics to 
show the features of the selected network. The sum of within-design Q statistics is used to 
assess the heterogeneity among direct comparisons (heterogeneity Q statistic), and the 
between-designs Q statistic is used to assess the inconsistency between direct and indirect 
evidence (inconsistency Q statistic). The I-squared statistic describes the percentage of 
variation across studies that is due to heterogeneity and inconsistency rather than chance. Since 
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we use random-effects model, the common heterogeneity standard deviation τ is used to 
indicate the extent of variation among the underlying effects in different studies. 
2. Two-dimensional plots that combines ORs for efficacy and acceptability. Each node in the 
plot indicates a drug. The plot has a fixed range on both x and y axis, to accommodate changes 
over time. Users can click on the plot to see a magnified version based on optimal ranges of x 
and y axis, displayed below the original graph. Placebo is used as the reference if placebo-
controlled trials are included, while citalopram as the reference if only head-to-head trials are 
included. We choose citalopram because it was the most consistently used antidepressant 
through these years26. Moreover, if the input includes placebo-controlled trials and both 
published and unpublished studies, the plot would have two sets of dots, one for full data and 
one for published studies only.  
3. Forest plots for both efficacy and acceptability: the ORs in both efficacy and acceptability 
between any two drugs are presented using forest plots against a common comparator. The 
reference drug is the same with two-dimensional plots.  
4. League tables: league tables that can show ORs in both efficacy and acceptability at 
comparison level are provided for users to download.  
5. Pairwise comparisons for both efficacy and acceptability: ORs for any two selected drugs 
as estimated from NMA are displayed on demand. 
6. Comparison-adjusted funnel plots for both efficacy and acceptability: if placebo-
controlled trials are included, the plots show all the RCTs that are directly compared with 
placebo. If only head-to-head trials are included, the plots show studies directly compared with 
fluoxetine only, since fluoxetine is the most frequently used active controls over time. 
7. Evidence evolution: the two-dimensional plots and league tables integrating the efficacy, 
acceptability and confidence in the evidence for 6 consecutive NMAs at 5-year intervals are 
presented. For the two-dimensional plots, we use a pie chart as a node for each drug, showing 
the distribution of the four-level evidence confidence for each drug. For the league tables, we 
colored each cell in terms of the overall confidence in evidence between two drugs: green 
indicated high, blue indicated moderate, yellow indicated low, and red indicated very low 
confidence in evidence. 
 
In the Results section, we present the colored league tables (at comparison level) and the pie charts 
integrated two-dimensional plots (at drug level) in terms of efficacy, acceptability and confidence in 
the evidence, at 5-year intervals since 1990. They reflect the evidence evolution. 
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RESULTS 
Included studies and characteristics of the network 
The dataset includes 190 head-to-head trials (179 trials with 33,428 patients for efficacy, and 174 
trials with 31,596 patients for acceptability, respectively) and 460 placebo-controlled trials; only the 
results from the former is are presented below. The study selection process (PRISMA flowchart), the 
references, characteristics and risk of bias assessment for all the included studies are in the Appendix 
(eFigure 1, eTable 1, and eTable 2). Figure 1 shows the network diagrams for efficacy from 1990 to 
2016. The network diagrams for acceptability are shown in the Appendix (eFigure 2).  
 
Changes in efficacy, acceptability and confidence in the evidence over time 
Figure 2 shows the league tables for efficacy (lower triangle) and acceptability (upper triangle) for 
each timepoint. In 1990s the evidence for most comparisons was of low or very low confidence, 
while after 2010 there was moderate or high confidence in the evidence for increasingly more 
comparisons. eFigure 3 and eFigure 4 in the Appendix illustrate the summary ORs for efficacy and 
acceptability against citalopram at each time point. We also generated the cumulative forest plot for 
each drug in efficacy compared with citalopram (eFigure 5). For drugs that we could observe for 
more than 20 years, most of them display a decrease in ORs except fluvoxamine. The comparison-
adjusted funnel plots (eFigure 6 and eFigure 7) do not suggest any important association between 
study results and study precision at any timepoint. The Appendix details the assessment of the 
confidence in the evidence (eTable 3-8 for efficacy and eTable 9-14 for acceptability). 
 
Figure 3 shows the two-dimensional plots at each time point, accommodating effects and the 
together with the confidence in evidence for each drug in comparison with citalopram. The graphs 
show that, as expected, precision for ORs improves over time. In 1990, all drugs were apparently 
more efficacious and acceptable than citalopram, but the confidence in the evidence was in general 
low due to imprecision as few RCTs were available. In 1995, two new drugs, venlafaxine and 
sertraline had relatively higher confidence in evidence compared with other drugs, though half of the 
evidence still had low credibility and the CIs were very wide. Venlafaxine outperformed in efficacy 
and sertraline in acceptability. Another two new drugs, bupropion and reboxetine, both had large 
ORs in efficacy, but the confidence in the evidence was low. In 2000, venlafaxine appeared to 
outperform all other drugs. Since many drugs in 2000 had lower ORs in efficacy compared to 1995, 
their effects are closer to citalopram’s and hence difficult to visually distinguish between them. At 
the same time, trazodone, fluvoxamine and clomipramine had worse efficacy, tolerability and 
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credibility in the evidence compared to other drugs. In 2005, new drugs were launched into the 
market, among which agomelatine stood out for its performance in efficacy and acceptability with 
moderate confidence in the evidence. Several drugs performed equally well, such as escitalopram, 
mirtazapine and paroxetine. Trazodone, fluvoxamine, clomipramine and reboxetine were found to 
have low efficacy, acceptability with low confidence in the evidence. In 2010, with further 
accumulation of studies, the confidence in the evidence improved overall. Agomelatine and 
escitalopram were presented as good options for both efficacy and acceptability. Finally, in 2016, 
vortioxetine was introduced and appeared to have the best efficacy and tolerability, however, the 
precision was very low. Our results implied that the findings for vortioxetine might be too optimistic 
and we should wait some years to see its real effect. 
 
Other than the figures displayed in this article, users can also explore the analyses which involve 
placebo-controlled trials in the web app. The comparison-adjusted funnel plots including placebo-
controlled trials for the whole dataset indicate statistically significant asymmetry (p value for Egger’s 
test is 0.0025 in both efficacy and acceptability). However, since the plots are not extremely 
asymmetrical, the small p value may due to the large number of RCTs. If changing the analysis to 
pooling more recent studies (e.g. after 1990), the test of asymmetry becomes insignificant. It 
suggests that the small-study effect may exist in old RCTs. The two-dimensional plots imply that the 
differences between active drugs are smaller at any time point when placebo-controlled trials are 
included. This phenomenon has been extensively discussed and possible explanations were given in 
a previous study20. Users can also get an appreciation of the magnitude of a potential publication bias 
when placebo-controlled trials are included from the two-dimensional figures. 
 
 
DISCUSSION 
To our knowledge, this is the first study to investigate and visualize the evolution of evidence 
concerning antidepressants in treating patients with acute phase major depression in the past 40 
years, based on efficacy, acceptability and confidence in evidence using cumulative NMAs. We 
developed a visualization tool via Shiny in R to facilitate the understanding of a massive amount of 
information produced about multiple analyses: multiple drugs, types of studies and time points for 
two outcomes and account of the credibility of the results. The web application captured the dynamic 
changes in efficacy and acceptability over time as new drugs were launched into the market and 
more and more trials completed. We observed that, initial results usually exaggerated the 
performance of newly approved drugs, and it took time to see the real effects, as was the case of 
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sertraline, venlafaxine, bupropion and many others. As the network became better populated with 
more studies and better connected over time, the overall confidence in the evidence improved. 
 
This is the first study to display the confidence in evidence together with the estimates of efficacy 
and acceptability for NMAs. Confidence in evidence is just as crucial to clinical decision making as 
effect size estimates themselves. In order to integrate 3 levels of information concurrently, we 
modified the league tables and two-dimensional figures. We used different colors of the cell to show 
the confidence of evidence for each comparison. If there are two or three candidate drugs to select 
from for a particular patient, it would be easy to check the relative effect and certainty of evidence 
between them in the league table. However, it is not easy to see the general performance for each 
drug from the league table, since it is comparison-based. Several studies adopted a two-dimensional 
graph to combine the efficacy and acceptability ORs for each drug3,27. In addition to these 
conventional two-dimensional graphs, we presented the certainty of evidence for each drug by 
illustrating the composition of four-level confidence in a small pie chart. It allows us to easily see 
that even though some drugs showed good efficacy and acceptability, if the evidence appeared to 
have low certainty, the recommendation of those drugs should be made with caution.  
 
As NMA is a method to synthesize massive data but yet produce a large amount of results, it is 
imperative to find a way to display their results more efficiently for physicians to comprehend. A 
powerful R package Shiny makes it easy to build interactive web apps straight from R. Within the 
Shiny application that we have developed, users can change some parameters and view the results of 
their own interest and to answer their own clinical questions.  
 
We observed that among drugs whose evolution of evidence we could observe for more than 20 
years, almost all of them (except fluvoxamine) showed noticeable reduction in the estimate of 
efficacy after being launched into the market, and it usually took more than 10 years to become 
stable. It indicates that new drugs tend to show overly enthusiastic performance when they are 
launched. This phenomenon has been observed in many other studies involving different medical 
specialties28-30. It was named variously, such as ‘wish bias’29, ‘the fading of reported effectiveness’30, 
or ‘novel agent effects’31. The inflated initial effects for new drugs were considered to be related to 
highly selected patients, small sample sizes, selective reporting, and publication bias in the early-
stage trials29,32,33. As a result, we should be particularly careful with the new drugs. Strategies such as 
improving the design, prespecifying rigorous analysis plans in the protocols, or encouraging prompt 
replications with bigger sample sizes, should be promoted for future early trials of new drugs32,34. 
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Meanwhile, accelerating evidence accumulation through evidence synthetic methods such as NMAs 
may also help. 
 
Rouse et al recently conducted similarly conceived retrospective NMAs for medications for open-
angle glaucoma at four to five-year intervals since 1991, in which the most efficacious drug 
remained to be prostaglandins since 199935. In our analysis by contrast, there were more dramatic 
changes in the recommendable drugs. Our results also show that the evidence can easily get out of 
date. It therefore follows that it is highly necessary to update evidence synthesis in a timely manner. 
Conducting NMAs from scratch is time-consuming36,37. However, if we conduct a prospective NMA 
according to the pre-specified procedures, we only need to update the dataset regularly. NMA may 
therefore be the most optimal method to synthesize evidence dynamically. In fact, the concept of 
living NMA, or sequential NMA, methodologically similar with retrospective cumulative NMA but 
with due attention to multiple testing issues, has already been proposed1,38-40. It can provide the 
theoretical basis for living systematic reviews and living guidelines for future practices of evidence-
based medicine37,41-43. 
 
Limitations 
Our study has several limitations. First, the confidence in evidence assessment via CINeMA 
inevitably involves subjective decisions, such as how to summarize average risk of bias or how to set 
the margin of equivalent effects. It is possible that different decisions might lead to different 
appraisal of the confidence in the evidence. To minimize the risk of post-hoc findings, we 
prespecified all the conventions in our protocol and we tried to make them clinically reasonable 
through discussions. Second, abstracting and summarizing the characteristics of the studies and 
lumping them across comparisons and drugs comes at the price of losing some important 
information. For example, aggregation of the level of confidence a to present drug-level judgements 
can conceal which comparisons and which confidence domains are responsible for the low 
confidence. Third, the acceptability of drugs was based on the overall discontinuation rate from 
RCTs, which might be slightly different from the concept of tolerability. Besides, RCTs are not the 
best method to evaluate long-term tolerability or adverse effects. Fourth, we conducted NMAs every 
5 years, which was somewhat arbitrary. However, we supposed that an interval of 5 years may 
suffice to capture the change in the evidence. On the web a newly developed interactive app enables 
analyses at any time points, though confidence assessment was only at 5-year interval. Finally, 
although our study illustrates the efficacy, acceptability and confidence in the evidence 
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simultaneously, the real recommendations to instruct clinical practice should also take cost-
effectiveness analysis or and specific side effects into consideration. 
 
 
CONCLUSION 
Our interactive visualization via Shiny in R captures the dramatic changes in evidence about the 
effects of antidepressants in the last 40 years, showing that initial results of new drugs are often 
exaggerated and that the overall confidence in the evidence improves over time. As a result, we 
should stay conservative towards new drugs, but speed up evidence accumulation and always keep 
the synthesized evidence up to date. 
 
 
Highlights 
• Network meta-analysis is considered to be a proper way of demonstrating the available 
evidence, since it allows comparisons between multiple interventions, and has been proved to 
be statistically powerful. 
• It is challenging to present the voluminous results of NMA in an efficient and comprehendible 
manner. 
• Evidence evolution based on the relatively new method NMA has not been investigated yet. 
• The results of NMA should not only include the effects but also the confidence in the evidence, 
which can help interpret the findings appropriately. 
• Effective use of rapidly developing statistical analysis and presentation tools such as shiny 
package in R, may facilitate and simplify the visualization of NMA output. 
• We should stay conservative towards new drugs, as their performance was often shown to be 
exaggerated initially, and it took time to become stable. 
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